Last reviewed · How we verify

NCT05109377

Endocan Level in Patients With Erectile Dysfunction and Relationship With Tadalafil Treatment

Status unknown NA Last updated 5 November 2021
What this trial tests

NA trial testing Endocan in Erectile Dysfunction in 90 participants. Status unknown.

Timeline
24 June 2021
Primary endpoint
15 November 2021
15 December 2021

Quick facts

Lead sponsorAnkara Training and Research Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposediagnostic
Enrollment90
Start date24 June 2021
Primary completion15 November 2021
Estimated completion15 December 2021
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Ankara Training and Research Hospital

Who can join

Adults 18 to 65, male only, with Erectile Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators analyze the patients' endocan levels, IIEF scores, and hormon levels both before and after tadalafil (5 or 20mg) treatment. The investigators want to see erectile dysfunction severity and tadalafil treatment relations with endocen level.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Erectile Dysfunction

Currently open trials in the same condition.

Other Ankara Training and Research Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05109377.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing